Announced Strategic Partnership with Mila to Expand AI Capabilities and Functionality of Antibody Development Platform
Advanced Lead Candidates for COVID-19 PolyTope™ Cocktail Therapy, Preclinical Trials Scheduled to Launch in January 2021
VICTORIA, BC, Dec. 21, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA ) (TSXV: IPA) (OTCQB: IPATF) today announced financial results for the second quarter of its 2021 fiscal year ended October 31, 2020.
Q2 Fiscal 2021 Financial Highlights:
Revenue was $4.8 million for the quarter ended October 31, 2020, an increase of $1.6 million, or 50%, compared to $3.2 million in the same quarter last year.
Adjusted EBITDA was $795,159 for the quarter ended October 31, 2020, an increase of $858,577 compared to ($63,418) in the same quarter last year.